See termination reason in detailed description.

The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults

The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.

Inclusion Criteria:

• Obese adults with a body mass index > or = 30 kg/m2; > or = to 27 kg/m2 for those with obesity-related comorbidities including hypertension and dyslipidemia

Exclusion Criteria:

• Pregnancy
• Diabetes
• Adults with serious or unstable current or past medical conditions